文献速递精神分裂症与精神病性障碍

大麻二酚对精神病临床高危人群内侧颞叶、中脑及纹状体功能障碍的影响:一项随机临床试验

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

这项在伦敦开展的平行组、双盲、安慰剂对照随机临床试验纳入33名未用药的精神病临床高危(CHR)参与者和19名健康对照,研究单次口服600 mg大麻二酚(CBD)对言语学习任务fMRI脑激活的影响。结果显示,安慰剂组在编码期右侧尾状核及回忆期海马旁回和中脑的激活低于对照,CBD组在上述三个区域的激活高于安慰剂组但低于对照组,呈中间水平;任务表现无显著组间差异。提示CBD可能部分正常化CHR相关的脑功能改变。

要点

  • 单次600 mg CBD可使CHR人群右侧尾状核、海马旁回及中脑的fMRI激活水平介于安慰剂组与健康对照之间。
  • 安慰剂组在编码期右侧尾状核及回忆期海马旁回/中脑的激活显著低于健康对照。
  • 三组间言语学习任务表现无显著差异,提示脑激活改变并非任务成绩差异所致。

核心结论

  • CBD可能部分正常化与CHR状态相关的海马旁回、纹状体及中脑功能改变,这些区域对精神病病理生理至关重要,或可解释其治疗精神病症状的作用。

研究设计与样本

  • 平行组、双盲、安慰剂对照随机临床试验,在英国伦敦South London and Maudsley NHS Foundation Trust开展。
  • 16名CHR参与者接受单次口服600 mg CBD,17名CHR参与者接受安慰剂,健康对照未用药;所有参与者执行言语学习任务时接受功能磁共振成像(fMRI)。

主要发现

  • 编码期右侧尾状核激活:安慰剂组中位数-0.027(IQR -0.041至-0.016),对照组中位数0.020(IQR -0.022至0.056),P < .001。
  • 回忆期海马旁回和中脑激活:安慰剂组中位数0.002(IQR -0.016至0.010),对照组中位数0.035(IQR 0.015至0.039),P < .001。
  • 上述三个区域中,CBD组激活高于安慰剂组但低于对照组(海马旁回/中脑:CBD组中位数-0.013,IQR -0.027至0.002;安慰剂组中位数-0.007,IQR -0.019至0.008;对照组中位数0.034,IQR 0.005至0.059),呈中间水平。
  • 任务表现无显著组间差异。

临床怎么用

  • 结果提示单次600 mg CBD可能部分改善CHR人群内侧颞叶、纹状体及中脑的脑功能异常,为CBD用于精神病高危人群的神经机制提供初步证据。
  • 研究为单次给药、小样本,尚不能直接支持临床常规使用CBD预防或治疗精神病。

局限性

  • 样本量小(CHR共33人,对照19人),且为单次给药设计,不能评估长期用药效果。
  • 脑激活分析实际纳入CBD组15人、安慰剂组16人、对照组19人,部分参与者数据未纳入分析。
  • 健康对照未接受安慰剂,组间比较可能受非特异因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cannabidiol (CBD) has antipsychotic effects in humans, but how these are mediated in the brain remains unclear. OBJECTIVE: To investigate the neurocognitive mechanisms that underlie the therapeutic effects of CBD in psychosis. DESIGN, SETTING, AND PARTICIPANTS: In this parallel-group, double-blind, placebo-controlled randomized clinical trial conducted at the South London and Maudsley NHS Foundation Trust in London, United Kingdom, 33 antipsychotic medication-naive participants at clinical high risk (CHR) of psychosis and 19 healthy control participants were studied. Data were collected from July 2013 to October 2016 and analyzed from November 2016 to October 2017. INTERVENTIONS: A total of 16 participants at CHR of psychosis received a single oral dose of 600 mg of CBD, and 17 participants at CHR received a placebo. Control participants were not given any drug. All participants were then studied using functional magnetic resonance imaging (fMRI) while performing a verbal learning task. MAIN OUTCOMES AND MEASURES: Brain activation during verbal encoding and recall, indexed using the blood oxygen level-dependent hemodynamic response fMRI signal. RESULTS: Of the 16 participants in the CBD group, 6 (38%) were female, and the mean (SD) age was 22.43 (4.95) years; of 17 in the placebo group, 10 (59%) were female, and the mean (SD) age was 25.35 (5.24) years; and of 19 in the control group, 8 (42%) were female, and the mean (SD) age was 23.89 (4.14) years. Brain activation (indexed using the median sum of squares ratio of the blood oxygen level-dependent hemodynamic response effects model component to the residual sum of squares) was analyzed in 15 participants in the CBD group, 16 in the placebo group, and 19 in the control group. Participants receiving placebo had reduced activation relative to controls in the right caudate during encoding (placebo: median, -0.027; interquartile range [IQR], -0.041 to -0.016; control: median, 0.020; IQR, -0.022 to 0.056; P < .001) and in the parahippocampal gyrus and midbrain during recall (placebo: median, 0.002; IQR, -0.016 to 0.010; control: median, 0.035; IQR, 0.015 to 0.039; P < .001). Within these 3 regions, activation in the CBD group was greater than in the placebo group but lower than in the control group (parahippocampal gyrus/midbrain: CBD: median, -0.013; IQR, -0.027 to 0.002; placebo: median, -0.007; IQR, -0.019 to 0.008; control: median, 0.034; IQR, 0.005 to 0.059); the level of activation in the CBD group was thus intermediate to that in the other 2 groups. There were no significant group differences in task performance. CONCLUSIONS AND RELEVANCE: Cannabidiol may partially normalize alterations in parahippocampal, striatal, and midbrain function associated with the CHR state. As these regions are critical to the pathophysiology of psychosis, the influence of CBD at these sites could underlie its therapeutic effects on psychotic symptoms. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN46322781.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bhattacharyya S, Wilson R, Appiah-Kusi E, et al. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 30167644. doi:10.1001/jamapsychiatry.2018.2309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。